TrimRx's Blog
Next-Generation GLP-1 Drugs: What’s New in 2026
The biggest change to the weight loss drug pipeline in 2026 is that several “coming soon” drugs have arrived. Three new options crossed the…
Foundayo (Orforglipron): The FDA-Approved Weight Loss Pill
Orforglipron is now approved and on the market under the brand name Foundayo. The FDA approved it on April 1, 2026, for adults with…
Does Wegovy Come in Pill Form? Yes, Here’s What to Know
Yes, Wegovy now comes in a pill. In December 2025, the FDA approved an oral version of Wegovy, a once-daily 25 mg semaglutide tablet,…
Wegovy HD (7.2 mg): The Highest Dose of Wegovy Explained
The highest approved dose of Wegovy is now 7.2 mg, sold as Wegovy HD. The FDA approved it in March 2026, and Novo Nordisk…
Amycretin vs Tirzepatide: How They Compare
Amycretin and tirzepatide aren’t really competitors yet, because only one of them is available. Tirzepatide (sold as Zepbound and Mounjaro) is FDA approved, on…
Survodutide vs Wegovy: How They Compare on Weight and Liver Health
Survodutide and Wegovy both use the GLP-1 pathway to reduce appetite, but they aren’t in the same place. Wegovy (semaglutide) is FDA approved and…
Amycretin vs Wegovy: Should You Wait for the Next-Gen Drug?
If you’re choosing between starting Wegovy now and holding out for amycretin, here’s the honest framing. Wegovy is FDA approved, widely available, and backed…
Survodutide vs CagriSema: Two Investigational Obesity Drugs Compared
Survodutide and CagriSema are both investigational obesity drugs, but they come from different companies and use different hormone combinations. Survodutide (Boehringer Ingelheim and Zealand…
Amycretin vs CagriSema: How Novo Nordisk’s Two Next-Gen Obesity Drugs Compare
Amycretin and CagriSema are both Novo Nordisk obesity programs that pair GLP-1 with amylin, two appetite hormones, but they go about it differently. CagriSema…
